When Anxiety Persists After an SSRI Trial
Anxiety disorders can affect work, relationships, sleep, physical health, and the ability to move through everyday life with confidence. Selective serotonin reuptake inhibitors, or SSRIs, provide meaningful relief for many people, but they do not work the same way for everyone.
Some people experience only partial improvement. Others have side effects that make it difficult to continue treatment, or they complete more than one medication trial without getting the relief they need. When that happens, it does not mean the anxiety is untreatable. It means the treatment plan deserves another careful look.
At Wholistic Health, we meet people from Mobile and communities throughout the Gulf Coast who have already invested significant time and effort in their mental health care. We do not assume that someone who is still struggling has failed treatment or has not tried hard enough. We look at what has and has not helped, consider the full clinical picture, and discuss which anxiety treatment options in the Mobile area may be appropriate.
Anxiety Is More Than an Overactive Alarm
Anxiety can involve racing thoughts, muscle tension, chest tightness, a rapid heartbeat, digestive changes, disrupted sleep, difficulty concentrating, hypervigilance, or a strong desire to avoid certain situations.
These symptoms involve several interacting brain circuits and body systems. The amygdala plays an important role in detecting potential threats, but anxiety cannot be reduced to one part of the brain or one chemical imbalance. Attention, memory, stress hormones, learned responses, physical health, genetics, and life experiences may all contribute.
Generalized anxiety disorder, panic disorder, social anxiety disorder, and specific phobias are also separate diagnoses. Although they can share certain symptoms, they may require different treatment strategies.
This is one reason we avoid treating persistent anxiety as a simple serotonin problem. SSRIs affect serotonin signaling, but the biology of anxiety is more complex. A medication that helps one person may provide limited benefit to another, even when both people have been given the same diagnosis.
What Does It Mean When an SSRI Does Not Work?
One unsuccessful medication trial does not prove that every SSRI will fail. Some people benefit from a different medication within the same class, an adjusted dose, a longer trial, or a change that improves tolerability. Depending on the diagnosis, a clinician may also consider another type of medication or recommend a specific form of psychotherapy.
Before describing an SSRI trial as unsuccessful, a provider should consider questions such as:
- Was the diagnosis accurate?
- Was the medication taken consistently?
- Did the dose and duration provide a fair trial?
- Did side effects prevent the person from reaching a useful dose?
- Did another medication or substance affect the response?
- Is a medical condition contributing to the symptoms?
- Are depression, trauma, chronic pain, or sleep problems complicating the picture?
- Has the patient had access to an appropriate form of psychotherapy?
Repeated nonresponse is still meaningful. When several reasonable treatment attempts have not produced enough improvement, it may be time to reassess the overall plan rather than simply repeat the same process.
We focus on the pattern rather than a single medication name. We want to understand what changed, what remained difficult, which side effects occurred, and how anxiety continues to affect daily functioning.
A Broader Plan May Include More Than Medication Changes
Next-step anxiety care does not always mean replacing one prescription with another. The most appropriate plan may include psychotherapy, medication adjustments, attention to co-occurring conditions, lifestyle support, or a discussion of interventional options.
Psychotherapy Still Matters
Evidence-based psychotherapy remains an important part of care for many anxiety disorders. The specific approach should match the diagnosis and the person’s needs.
A patient who has not benefited from medication may still respond to psychotherapy, particularly when treatment addresses avoidance patterns, distressing thoughts, trauma responses, or behaviors that reinforce anxiety. Medication and psychotherapy can also be used together rather than viewed as competing choices.
We do not want the search for a new biological treatment to obscure other parts of care that may still be useful.
IV Ketamine for Anxiety Is an Off-Label Option
Ketamine works differently from SSRIs. Its effects involve the glutamate system and NMDA receptors rather than relying primarily on serotonin signaling. Researchers have studied whether this different mechanism may help people with anxiety that has not responded to standard treatments.
Small clinical trials and research reviews have reported reductions in symptoms among some people with refractory anxiety-spectrum disorders, including social anxiety disorder. However, this evidence remains limited compared with the research supporting established treatments for anxiety. Studies have generally involved relatively small groups, different dosing methods, and limited follow-up.
For that reason, we present IV ketamine treatment carefully and transparently. Ketamine is not FDA-approved for anxiety disorders. Its psychiatric use for anxiety is off-label, and no individual result can be predicted or guaranteed.
A consultation is not a promise that ketamine will be recommended. We first consider the diagnosis, medical history, previous treatment, current medications, potential risks, and whether another established treatment should be addressed first.
People who are also experiencing significant depression may find it helpful to read our overview of IV ketamine for depression, because the evidence and clinical context are not identical to ketamine use for a standalone anxiety disorder.
TMS May Be Relevant When Depression Is Also Present
Transcranial magnetic stimulation, or TMS, is a noninvasive treatment that uses magnetic pulses to stimulate targeted areas of the brain. At Wholistic Health, our current NeuroStar TMS program is presented primarily for depression.
That distinction matters. TMS should not automatically be described as a treatment for generalized anxiety disorder, panic disorder, or every other anxiety diagnosis simply because a person has not responded to an SSRI.
Many people with depression also experience prominent anxiety symptoms. When anxiety occurs alongside a qualifying depressive illness, TMS may be considered as part of the depression treatment plan. Treating the depression may also influence some associated anxiety symptoms, but the evaluation must remain focused on the person’s actual diagnoses and the cleared treatment protocol.
Our guide to FDA-cleared TMS for depression explains how the treatment works, what a typical course may involve, and why it can be considered when antidepressant medication has not provided enough relief.
TMS does not involve systemic medication or sedation, but it is still a medical treatment with eligibility considerations, possible side effects, and a significant time commitment. We discuss those realities before recommending a course of care.
We Look at the Whole Clinical Picture
Anxiety rarely exists in complete isolation. Depression, post-traumatic stress, chronic pain, sleep disruption, hormonal changes, medication effects, substance use, and medical conditions can all shape how anxiety feels and how it responds to treatment.
Someone with anxiety and major depression may need a different plan from someone whose primary concern is panic disorder. A person whose symptoms intensified after a medication change may need a different evaluation from someone who has experienced persistent anxiety for years.
At Wholistic Health, our whole-person approach means that we do not focus only on the symptom that feels most urgent that day. We review the medical and mental health history, current medications, previous treatment responses, physical concerns, and practical factors that may affect care.
That broader view also helps us avoid recommending an interventional treatment simply because it is available. Our role is to help determine whether it fits the patient’s needs. If antidepressants are part of the picture, our post on when antidepressants stop working may provide useful context for what comes next.
Anxiety Can Make It Harder to Ask for Help
One of the most difficult barriers to specialized anxiety care is the anxiety itself.
Calling a new clinic, meeting a new provider, describing years of symptoms, or considering an unfamiliar treatment can feel overwhelming. Anticipatory anxiety may lead someone to postpone the conversation repeatedly, even when current treatment is not working.
We understand that hesitation. Our team can answer general questions about our services and explain what to expect before a treatment decision is made. Gathering information does not obligate you to begin a procedure or discontinue your current care.
It is also important to remember that anxiety is not a character flaw. Persistent anxiety is not proof that someone is weak, overly sensitive, or incapable of handling life. Anxiety disorders are health conditions influenced by biological, psychological, environmental, and social factors.
Needing another treatment approach is not a personal failure. It is a reason for a more complete evaluation.
Questions We Hear About Next-Step Anxiety Care
Can IV ketamine help if antidepressants have not worked?
Research suggests that ketamine may reduce symptoms for some people with refractory anxiety-spectrum disorders, but the evidence is still developing. Ketamine for anxiety is an off-label use and is not FDA-approved for generalized anxiety disorder, panic disorder, social anxiety disorder, or other standalone anxiety conditions.
We evaluate candidacy individually and discuss both the limitations of the evidence and the potential risks before making a recommendation.
What is the difference between TMS for depression and TMS for anxiety?
TMS devices and protocols have specific FDA-cleared indications. At Wholistic Health, our current TMS service is focused on depression.
A person with major depression may also experience significant anxiety symptoms, and those symptoms are considered during the evaluation. That is different from using TMS as a general treatment for a standalone anxiety disorder. We review the diagnosis before determining whether TMS is clinically appropriate.
How long should I try an SSRI before considering another option?
There is no single timeline that applies to every medication or patient. Providers consider the prescribed dose, how consistently it was taken, how long it was used, side effects, the diagnosis being treated, and whether any improvement occurred.
Antidepressants commonly require several weeks before their benefit can be judged. Do not stop, reduce, or switch a psychiatric medication without guidance from the prescribing provider.
Does considering ketamine or TMS mean I must stop my current medication?
Not necessarily. Some patients continue existing medications while receiving an interventional treatment, while others may need an adjustment based on their health history or the medication involved.
We review current prescriptions during the evaluation and coordinate with the prescribing clinician when appropriate. Medication changes should be planned rather than made abruptly.
Is anxiety treatment covered by insurance?
Coverage depends on the service, diagnosis, treatment history, and individual plan.
TMS coverage is generally connected to a qualifying depression diagnosis and plan-specific medical-necessity criteria. IV ketamine for anxiety is an off-label treatment, so insurance coverage may be limited. SPRAVATO® is a separate treatment with FDA-approved depression indications and is not an approved treatment for standalone anxiety. Our article explaining what SPRAVATO® is and who may qualify provides more context.
Our team can explain current pricing and any applicable benefits-verification process, but final coverage decisions are made by the insurer.
What to Remember When SSRIs Are Not Enough
- One unsuccessful SSRI trial does not mean that every medication in the class will fail.
- Repeated nonresponse is a reason to reassess the diagnosis, medication history, psychotherapy, medical factors, and co-occurring conditions.
- IV ketamine uses a different pharmacological mechanism, but ketamine for anxiety remains off-label and the research is still limited.
- Our TMS program is focused on depression and should not be presented as a general treatment for every anxiety disorder.
- Anxiety is a health condition, not a character flaw or evidence that someone has failed treatment.
- Every recommendation should follow an individualized review of potential benefits, limitations, risks, and alternatives.
A Different Treatment Conversation May Be the Next Step
Anxiety that continues after more than one medication trial does not mean that nothing can help. It means the next decision should be based on a fuller understanding of the diagnosis, previous treatment, co-occurring concerns, and the person’s goals.
At Wholistic Health, we offer patients from Mobile and the surrounding Gulf Coast an honest conversation about what may come next. Sometimes that conversation supports another established medication or psychotherapy strategy. In other cases, an interventional option may be worth considering.
We do not expect patients to arrive with the answer. Our role is to help review the history, explain the options clearly, and determine whether one of our services fits the clinical picture.
To ask questions or discuss an evaluation at our Theodore clinic, contact our Wholistic Health team.
How We Approach Anxiety Care at Wholistic Health
At Wholistic Health, we combine traditional medical care with a whole-person perspective that considers mental, physical, and lifestyle factors. We serve patients from Theodore, Mobile, and surrounding Gulf Coast communities.
Our clinic offers IV ketamine for selected mood and pain conditions and NeuroStar TMS for depression. We evaluate each person individually and do not promise that a particular treatment will be recommended or produce a specific result.
Our goal is to provide clear information, compassionate care, and realistic expectations so that each patient can make an informed decision with the appropriate clinical guidance. You can learn more about our approach on our About Us page.
Works Cited
National Institute of Mental Health. (n.d.). Anxiety disorders. U.S. Department of Health and Human Services. https://www.nimh.nih.gov/health/topics/anxiety-disorders
National Institute of Mental Health. (n.d.). Brain stimulation therapies. U.S. Department of Health and Human Services. https://www.nimh.nih.gov/health/topics/brain-stimulation-therapies/brain-stimulation-therapies
Taylor, J. H., Landeros-Weisenberger, A., Coughlin, C., Mulqueen, J., Johnson, J. A., Gabriel, D., Reed, M. O., & Jakubovski, E. (2018). Ketamine for social anxiety disorder: A randomized, placebo-controlled crossover trial. Neuropsychopharmacology, 43(2), 325–333. doi:10.1038/npp.2017.194 https://pmc.ncbi.nlm.nih.gov/articles/PMC5729569/
U.S. Food and Drug Administration. (2008). NeuroStar TMS Therapy System 510(k) summary. Center for Devices and Radiological Health. https://www.accessdata.fda.gov/cdrh_docs/pdf8/k083538.pdf
U.S. Food and Drug Administration. (2025). SPRAVATO® esketamine nasal spray prescribing information. Center for Drug Evaluation and Research. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s016lbl.pdf
Whittaker, E., Dadabayev, A. R., Joshi, S. A., & Glue, P. (2021). Systematic review and meta-analysis of randomized controlled trials of ketamine in the treatment of refractory anxiety spectrum disorders. Therapeutic Advances in Psychopharmacology, 11, 20451253211056743. doi:10.1177/20451253211056743 https://pmc.ncbi.nlm.nih.gov/articles/PMC8679040/
Medical Disclaimer
This content is provided for educational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any condition. Treatment outcomes vary, and a service that is appropriate for one person may not be appropriate for another.
IV ketamine for anxiety disorders is an off-label use and is not FDA-approved for anxiety. NeuroStar TMS has specific FDA-cleared indications, including major depressive disorder, and should not be described as a general FDA-cleared treatment for standalone anxiety disorders. SPRAVATO® has separate FDA-approved depression indications and is not an approved treatment for standalone anxiety.
Always speak with a qualified healthcare provider before starting, stopping, or changing a mental health treatment. If you are experiencing a mental health crisis or thoughts of suicide, call or text 988 or go to the nearest emergency room.